Catherine McNamara
Nurse Practitioner · Reno, NVNPI 1649364613
Payments from drug & device makers
Across 235 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$974
- AstraZeneca$697
- Pfizer$364
- GSK$324
- Novo Nordisk$295
- Lilly USA, LLC$275
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,450100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $974 |
| AstraZeneca | 35 | $697 |
| Pfizer | 18 | $364 |
| GSK | 20 | $324 |
| Novo Nordisk | 15 | $295 |
| Lilly USA, LLC | 15 | $275 |
| Merck | 9 | $169 |
| Amgen | 6 | $159 |
| Idorsia Pharmaceuticals US Inc | 9 | $144 |
| Astellas Pharma US Inc | 4 | $118 |
| Boehringer Ingelheim | 7 | $110 |
| Johnson & Johnson | 3 | $70 |
| Bayer | 4 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $61 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| Abbott | 3 | $57 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Boston Scientific | 2 | $53 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| Corcept Therapeutics | 2 | $46 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Alfasigma USA, Inc. | 1 | $33 |
| UCB, Inc. | 2 | $33 |
| Medtronic | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $20 |
| Lucid Diagnostics Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
How this compares
$4,450 in reported general payments places this provider in the 90th percentile of 933 nurse practitioner providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 102 | $109,682 |
| MounjaroTirzepatide | 43 | $53,384 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $46,153 |
| JardianceEmpagliflozin | 38 | $44,356 |
| EliquisApixaban | 41 | $39,620 |
| RybelsusSemaglutide | 14 | $30,047 |
| TrulicityDulaglutide | 17 | $22,275 |
| FarxigaDapagliflozin Propanediol | 20 | $19,107 |
| ProliaDenosumab | 11 | $17,980 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $14,524 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $14,016 |
| MyrbetriqMirabegron | 13 | $9,910 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,657 |
| QuviviqDaridorexant Hcl | 11 | $5,114 |
| Atorvastatin Calcium | 263 | $4,170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $295 | $139,729116 claims |
| Lilly USA, LLCMounjaro, Trulicity | $275 | $75,65960 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $324 | $53,80977 claims |
| Boehringer IngelheimJardiance | $110 | $44,35638 claims |
| PfizerEliquis | $364 | $39,62041 claims |
| AstraZenecaFarxiga | $697 | $19,10720 claims |
| AmgenProlia | $159 | $17,98011 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $60 | $14,52413 claims |
| Astellas Pharma US IncMyrbetriq | $118 | $9,91013 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $144 | $5,11411 claims |
| AbbVieSynthroid | $974 | $2,29331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 nurse practitioner providers in Nevada.
Other nurse practitioner in Reno
- Melissa DelamoraReno$20K
- Darian ThorpReno$18K
- Mary Beth MedinaReno$11K
- Kristen BowmanReno$10K
- Laura HayReno$8K
- Laura HarshReno$7K
- Mary HelmreichReno$7K
- Rhonda StrunkReno$7K
- Rachael HueftleReno$7K
- Rhonda NavarroReno$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.